Clinical trial
1stline Study Capecitabine Administered on Continuous Way Plus…
NCT00345696 · Unidad Integral de Investigación en Oncología S.L., Other · Completed
Key facts
| NCT number | NCT00345696 |
|---|---|
| Title | 1stline Study Capecitabine Administered on Continuous Way Plus Oxaliplatin&Bevacizumab Every 2weeks in Metastatic CCR. |
| Official title | Phase II Study of First Line Capecitabine Administered on Continuous Way Combined With Oxaliplatin and Bevacizumab Every Two Weeks in Metastatic Colorectal Cancer Patients. |
| Lead sponsor | Unidad Integral de Investigación en Oncología S.L., Other |
| Collaborators | Hoffmann-La Roche Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Metastatic Colorectal Cancer |
| Intervention type | Drug |
| Interventions | Bevacizumab, Capecitabine, Oxaliplatine |
| Enrollment | 32 |
| Start date | Jun 1, 2006 |
| Primary completion | Oct 1, 2008 |
| Completion | Jan 1, 2011 |
| First posted | Jun 28, 2006 |
| Last update posted | Aug 24, 2011 |
| Countries | Spain |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: